Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in neovascular age-related macular degeneration (AMD), we conducted a systematic review and meta-analysis to evaluate the long-term safety profiles of these agents, including ocular safety.

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies / Plyukhova, Aa; Budzinskaya, Mv; Starostin, Km; Rejdak, R; Bucolo, C; Reibaldi, M; Toro, Md.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:5(2020), p. 1522. [10.3390/jcm9051522]

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies

Toro MD.
2020

Abstract

Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in neovascular age-related macular degeneration (AMD), we conducted a systematic review and meta-analysis to evaluate the long-term safety profiles of these agents, including ocular safety.
2020
Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies / Plyukhova, Aa; Budzinskaya, Mv; Starostin, Km; Rejdak, R; Bucolo, C; Reibaldi, M; Toro, Md.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:5(2020), p. 1522. [10.3390/jcm9051522]
File in questo prodotto:
File Dimensione Formato  
16. jcm-09-01522.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 2.01 MB
Formato Adobe PDF
2.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/894767
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 51
  • ???jsp.display-item.citation.isi??? ND
social impact